T1	Participants 1202 1333	We conclude that acyclovir is better than vidarabine for the treatment of varicella-zoster infection in immunocompromised patients.
T2	Participants 374 416	Eleven patients were treated in each group
T3	Participants 140 372	In a prospective, randomized trial, we compared intravenous acyclovir and vidarabine in the treatment of varicella-zoster virus infection in severely immunocompromised patients who presented within 72 hours of onset of the infection
T4	Participants 86 137	A randomized comparison of acyclovir and vidarabine
